Cabaletta Bio
Yahoo Finance • last year
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
PHILADELPHIA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseas... Full story
Yahoo Finance • last year
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clinical site actively recruiting patients – – Expanded CABA-201 clinical develo... Full story
Yahoo Finance • last year
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
– First cleared CD19-CAR T IND application for generalized myasthenia gravis announced in the U.S. and fourth IND clearance for CABA-201 across a broad range of autoimmune diseases – – Clearance expands the clinical development of CABA-20... Full story
Yahoo Finance • last year
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseas... Full story
Yahoo Finance • last year
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
– Third IND application clearance for CABA-201 within the past 6 months across a broad range of autoimmune diseases – – Phase 1/2 clinical trial evaluating CABA-201 in systemic sclerosis features parallel cohort design and the same starti... Full story
Yahoo Finance • last year
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
PHILADELPHIA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune disea... Full story
Yahoo Finance • last year
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
PHILADELPHIA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseas... Full story
Yahoo Finance • last year
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
– Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts – – Partnership for CABA-201 builds on existing manufac... Full story
Yahoo Finance • 2 years ago
Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLO... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio Announces Pricing of Public Offering of Common Stock
PHILADELPHIA, May 17, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for p... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio Announces Proposed Public Offering of Common Stock
Cabaletta Bio PHILADELPHIA, May 17, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell th... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis
– Phase 1/2 trial for CABA-201 planned to initiate in patients with myositis at an initial dose that is equivalent to the dose used in a patient with myositis as reported in the recent Lancet Rheumatology publication – – Second IND cleara... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update
– IND application cleared within 30 days for clinical trial of CABA-201 in patients with LN and SLE and Fast Track Designation granted by the FDA for CABA-201 to deplete CD19-positive B cells and improve disease activity in patients with L... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting
PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune disease... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio Receives FDA Fast Track Designation for CABA-201
PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune disease... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
PHILADELPHIA, April 25, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune disea... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
PHILADELPHIA, April 13, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune disea... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus
– IND application cleared within 6 months of in-licensing CABA-201 binder – – CABA-201 data package and experience from prior autoimmune cell therapy INDs informed Phase 1/2 clinical trial design, including the initial dose to be evaluate... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
– Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell therapy, with potential to generate initial clinical data by the first half of 2024 – PHIL... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference
PHILADELPHIA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseas... Full story
